Tysabri, also known by its generic name natalizumab, is a medication used to treat multiple sclerosis (MS) and Crohn’s disease. It is classified as a monoclonal antibody and works by targeting specific immune cells in the body to reduce inflammation and prevent damage to the nervous system.

For patients with relapsing forms of MS, Tysabri has been shown to significantly reduce the frequency of relapses and slow the progression of disability. It is typically prescribed for individuals who have not responded well to other disease-modifying therapies or who have severe forms of the disease.

In the case of Crohn’s disease, Tysabri is used to reduce inflammation in the intestines and improve symptoms such as abdominal pain, diarrhea, and weight loss. It is often recommended for patients who have not had success with other treatments or who have moderate to severe disease activity.

As with any medication, Tysabri does come with potential side effects, including an increased risk of infections, liver damage, and allergic reactions. Patients receiving Tysabri are typically monitored closely by their healthcare provider to ensure the medication is working effectively and to watch for any adverse reactions.

It is important for patients to discuss their medical history and any other medications they are taking with their healthcare provider before starting Tysabri. Additionally, regular blood tests may be required to monitor for any potential complications.

Overall, Tysabri can be a valuable treatment option for individuals with MS or Crohn’s disease who have not responded well to other therapies. By working closely with their healthcare team, patients can effectively manage their condition and improve their quality of life.